How many stocks are there of Ucb?
The current number of stocks of Ucb is 195.19 M undefined.
Ucb Stocks 2024
Ucb Stocks
195.19 M
Ticker
UCB.BR
ISIN
BE0003739530
WKN
852738
In 2024, Ucb had 195.19 M outstanding stocks, a 0% change from the 195.19 M stocks in the previous year.
The Ucb Stocks history
| YEAR | NUMBER OF STOCKS (undefined EUR) |
|---|---|
| 2029e | 195.19 |
| 2028e | 195.19 |
| 2027e | 195.19 |
| 2026e | 195.19 |
| 2025e | 195.19 |
| 2024e | 195.19 |
| 2023 | 195.19 |
| 2022 | 194.83 |
| 2021 | 194.18 |
| 2020 | 189.03 |
| 2019 | 187.22 |
| 2018 | 188.48 |
| 2017 | 188.28 |
| 2016 | 188.37 |
| 2015 | 192.08 |
| 2014 | 190.46 |
| 2013 | 182.2 |
| 2012 | 190.4 |
| 2011 | 196.6 |
| 2010 | 184.2 |
| 2009 | 186.4 |
| 2008 | 180.2 |
| 2007 | 183.4 |
| 2006 | 147.7 |
| 2005 | 146.1 |
| 2004 | 145.9 |
Ucb shares outstanding BE0003739530 · 852738
The number of shares was Ucb in 2023 — This indicates how many shares 195.19 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.
3 years
5 years
10 years
25 Years
Max
Number of stocks
Details
Revenue, EBIT and Earnings per share
ⓘRevenue Per Share
Revenue per share represents the total revenue Ucb earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.
EBIT Per Share
EBIT per share indicates Ucb's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.
Income Per Share
Income per share, or earnings per share (EPS), reveals the portion of Ucb’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.
Expected Values
Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Ucb's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.
| Number of stocks | |
|---|---|
| 2004 | 145.9 M Aktien |
| 2005 | 146.1 M Aktien |
| 2006 | 147.7 M Aktien |
| 2007 | 183.4 M Aktien |
| 2008 | 180.2 M Aktien |
| 2009 | 186.4 M Aktien |
| 2010 | 184.2 M Aktien |
| 2011 | 196.6 M Aktien |
| 2012 | 190.4 M Aktien |
| 2013 | 182.2 M Aktien |
| 2014 | 190.46 M Aktien |
| 2015 | 192.08 M Aktien |
| 2016 | 188.37 M Aktien |
| 2017 | 188.28 M Aktien |
| 2018 | 188.48 M Aktien |
| 2019 | 187.22 M Aktien |
| 2020 | 189.03 M Aktien |
| 2021 | 194.18 M Aktien |
| 2022 | 194.83 M Aktien |
| 2023 | 195.19 M Aktien |
| 2024e | 195.19 M Aktien |
| 2025e | 195.19 M Aktien |
| 2026e | 195.19 M Aktien |
| 2027e | 195.19 M Aktien |
| 2028e | 195.19 M Aktien |
| 2029e | 195.19 M Aktien |
Ucb Aktienanalyse
What does Ucb do?
The company UCB SA is a Belgian pharmaceutical company that was founded in 1928 and is now active worldwide. The business model of UCB SA is based on the discovery and development of medications for severe diseases. The core competencies of the company are in neurology, immunology, and cardiology. In the history of UCB SA, there are several milestones. In 1961, UCB SA succeeded in synthesizing antihistamines, which marked the beginning of the development of medications for allergic diseases. In the 1990s, UCB SA began to focus on the development of medications for the treatment of epilepsy and Parkinson's disease. In the 2000s, UCB SA acquired several companies, expanding its portfolio of medications and its geographic reach. The company operates three different divisions: pharmaceuticals, biopharmaceuticals, and specialty chemicals. In the pharmaceuticals division, UCB SA develops and distributes medications for the treatment of epilepsy, Parkinson's disease, and autoimmune diseases such as rheumatoid arthritis and lupus. UCB SA's biopharmaceutical division focuses on researching antibodies for the treatment of various diseases such as cancer and multiple sclerosis. In the specialty chemicals division, UCB SA produces chemical products such as solvents and paints. The company offers a wide range of products tailored to the needs of patients with various diseases. One example of a well-known product from UCB SA is Keppra, a medication for the treatment of epilepsy. Keppra is one of the most prescribed medications for epilepsy and has helped improve the lives of millions of patients. Another example is Cimzia, a medication for the treatment of rheumatoid arthritis, Crohn's disease, and ulcerative colitis. Cimzia belongs to a new generation of medications that aim to selectively influence the immune system and thus inhibit inflammation. UCB SA places great value on innovation and constantly researches new medications and therapies. The company has a strong research and development team with over 3,000 employees and invests approximately 25% of its revenue annually in the research and development of new medications. Overall, UCB SA is an innovative and successful pharmaceutical company with a broad portfolio of medications and a strong commitment to the quality of the products developed. The company is dedicated to improving the lives of patients with severe diseases and remains a key player in the global pharmaceutical industry in the long term. Ucb ist eines der beliebtesten Unternehmen auf Eulerpool.com.Stocks Details
Evaluating Ucb's Shares Outstanding
Ucb's shares outstanding refer to the total number of shares that are currently held by all its shareholders, including institutional investors and restricted shares held by the company’s officers and insiders. The number of shares outstanding is crucial in determining the company's market capitalization and is used by investors to assess the company’s size, financial health, and investment potential.
Year-to-Year Comparison
Tracking the changes in Ucb’s shares outstanding over the years can provide investors with insights into the company's financial strategies and market valuation. An increase in shares outstanding can result from actions like issuing new shares, while a decrease can result from buybacks.
Impact on Investments
For investors, understanding Ucb’s shares outstanding is essential for evaluating its earnings per share (EPS) and market valuation. A change in the number of shares outstanding can impact the EPS, which is a significant driver of stock prices and investor decisions.
Interpreting Changes in Shares Outstanding
Variances in Ucb’s shares outstanding can signal shifts in the company’s financial strategy. An increase may dilute the EPS and share value, indicating potential fundraising or acquisitions. Conversely, a decrease, often due to share buybacks, can enhance share value and indicate the company’s confidence in its financial performance.
Frequently Asked Questions about Ucb stock
What does Number of Shares / OutstandingShares mean?
The outstanding shares (or issued shares) of Ucb are the total number of shares issued and actively held by shareholders - both external investors and company insiders. However, these must be actual shares. may grant stock options to executives that can be converted into shares.
How has the number of shares of Ucb evolved in recent years?
The number of shares of Ucb has increased by 0% gestiegen compared to last year.
What does the number of shares mean for investors?
The number of shares outstanding is used to calculate key metrics such as a company's market capitalization, earnings per share (EPS), and cash flow per share (CFPS). The number of outstanding shares of a company is not static and can fluctuate greatly over time.
Why does the number of stocks fluctuate?
There are various factors that can lead to a change. Ucb as a company can issue new shares, carry out stock splits or reverse splits.
Does the number of shares have an impact on the performance of Ucb?
There is no tangible long-term evidence or study that stocks with a certain number of shares (regardless of Mega/Large/Mid/Small Cap) would yield significantly higher returns than others. There are occasional small studies (limited number of stocks, short investment period) that certain classes outperform or have higher risk, but none of them are 1. conclusive (cause-effect is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).
How much dividend does Ucb pay?
Over the past 12 months, Ucb paid a dividend of 1.33 EUR . This corresponds to a dividend yield of about 0.74 %. For the coming 12 months, Ucb is expected to pay a dividend of 1.36 EUR.
What is the dividend yield of Ucb?
The current dividend yield of Ucb is 0.74 %.
When does Ucb pay dividends?
Ucb pays a quarterly dividend. This is distributed in the months of May, May, May, May.
How secure is the dividend of Ucb?
Ucb paid dividends every year for the past 26 years.
What is the dividend of Ucb?
For the upcoming 12 months, dividends amounting to 1.36 EUR are expected. This corresponds to a dividend yield of 0.76 %.
In which sector is Ucb located?
Ucb is assigned to the 'Health' sector.
Wann musste ich die Aktien von Ucb kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Ucb from 4/30/2024 amounting to 1.36 EUR, you needed to have the stock in your portfolio before the ex-date on 4/26/2024.
When did Ucb pay the last dividend?
The last dividend was paid out on 4/30/2024.
What was the dividend of Ucb in the year 2023?
In the year 2023, Ucb distributed 1.3 EUR as dividends.
In which currency does Ucb pay out the dividend?
The dividends of Ucb are distributed in EUR.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Ucb
Our stock analysis for Ucb Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Ucb Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
